In a nutshell
This study investigated the effectiveness and safety of tadalafil (Cialis) plus mirabegron (Myrbetriq) in the treatment of overactive bladder (OAB). Researchers suggested that this combined treatment improves symptoms caused by OAB.
Some background
OAB consists of a frequent feeling of needing to urinate. It negatively impacts the quality of life of these patients. OAB can also be a symptom of other conditions such as benign prostatic hyperplasia (enlargement of the prostate gland). Due to this change in size, the prostate compresses the urinary tube stopping the flow of urine.
Recently, mirabegron was shown to improve OAB symptoms with fewer side effects when compared to other drugs. Tadalafil has recently been used for the treatment of lower urinary symptoms with improved outcomes. However, the effectiveness of these two drugs combined for patients with OAB is still not known.
Methods & findings
This study included information about 176 male patients with OAB. These patients were assigned to receive tadalafil alone (87) or tadalafil and mirabegron combination (89). The study lasted for 12 weeks.
The total OAB symptoms decreased in the combination group when compared to tadalafil alone. This included improvements in urinating at night-time, urgency, and incontinence (urine leakage).
One moderate side effect (pain in the hip) was reported. However, the association with therapy was not established. Seven mild effects were reported in each group. These included diarrhea, bladder discomfort, swelling in the legs, or rash.
The bottom line
This study showed an improved effectiveness for the combined therapy tadalafil/mirabegron for OAB with fewer side effects.
The fine print
This study was funded by Astellas Pharma, the mirabegron manufacturer.
Published By :
Neurourology and urodynamics
Date :
Jan 21, 2020
